EMA Authorised: Scintimun (besilesomab) — Telix Innovations

View source ↗

Summary

Authorised medicinal product Scintimun (besilesomab) with indications in osteomyelitis and radionuclide imaging.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomyelitis

Drugs mentioned

• Scintimun (besilesomab)

Snippet

Status: Authorised. Therapeutic area: Osteomyelitis;Radionuclide Imaging. MAH: Telix Innovations. Decision date: 09/06/2026